Thursday, April 08, 2021 12:09:24 PM
BWIS,
The question I posed is somewhat rhetorical as I believe that Kat’s Cure and Mr. Power represented only 2 potential opportunities for NWBO and INMune Bio to team up with a combo type of treatment outside of the Phase 3 trial because of the gravity of their situations. I believe there was a 2 for 2 cure rate with this combo tech. Care to try and estimate a value on that and maybe comment on why you would want to keep that quiet while you can still maintain control of the company? In my opinion Linda Powers has unbelievable leverage right now as long as what she has in her hands is under appreciated because no one knows except a very select group and longs aren’t selling out cheap but would be tempted to by any rise after TLD. I believe Kristin Power will act as Canadian liaison for patients, doctors and potential investors and that location is not as important as skill set, knowledge and enthusiasm. Best wishes
The question I posed is somewhat rhetorical as I believe that Kat’s Cure and Mr. Power represented only 2 potential opportunities for NWBO and INMune Bio to team up with a combo type of treatment outside of the Phase 3 trial because of the gravity of their situations. I believe there was a 2 for 2 cure rate with this combo tech. Care to try and estimate a value on that and maybe comment on why you would want to keep that quiet while you can still maintain control of the company? In my opinion Linda Powers has unbelievable leverage right now as long as what she has in her hands is under appreciated because no one knows except a very select group and longs aren’t selling out cheap but would be tempted to by any rise after TLD. I believe Kristin Power will act as Canadian liaison for patients, doctors and potential investors and that location is not as important as skill set, knowledge and enthusiasm. Best wishes
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
